pharmaceutical industry
Microsoft CEO Satya Nadella: AI Expanding the Frontier of Innovation Across Industries
Dec 12, 2025 03:29 pm CST
Microsoft CEO Satya Nadella, speaking at the Microsoft AI Tour in Mumbai, explained how artificial intelligence is fundamentally changing innovation possibilities across sectors. He emphasized that AI requires new development approaches, with organizations needing to integrate data, tools and workflows while embracing both unlearning and learning to adapt to this rapidly evolving technological frontier.
FDA Proposal Set to Cut Biocon's Biosimilar Development Costs by Half: Impact on Global Healthcare Access
Nov 14, 2025 03:04 am CST
India's Biocon anticipates a 50% reduction in biosimilar development costs following the FDA's proposal to simplify clinical testing requirements. The company, which reported 25% growth in biosimilar revenue and holds significant U.S. market share for oncology medications, plans to launch 20 biosimilars by 2030 while expanding into the weight-loss drug market.
Trump's 100% Pharmaceutical Tariffs: Global Impact on Countries and Companies
Sep 26, 2025 10:59 pm CST
President Trump's announcement of 100% tariffs on imported branded pharmaceuticals has sent shockwaves through the global drug industry. This policy, set to take effect in five days unless companies begin constructing US manufacturing facilities, threatens international pharmaceutical trade worth $252 billion annually. While the European Union claims protection through an existing trade agreement, countries like Switzerland and Denmark face significant risks. Pharmaceutical giants have already pledged $300 million in US investments as companies scramble to adapt to this protectionist measure that exempts generic medications but targets patented drugs.
Trump Announces 100% Tariff on Pharmaceutical Imports Unless Companies Build US Manufacturing Plants
Sep 26, 2025 11:42 am CST
President Donald Trump has announced 100% tariffs on pharmaceutical imports effective October 1, 2025, with exemptions for companies actively constructing manufacturing facilities in the US. The policy could significantly impact India's pharmaceutical sector, which exports over $3.6 billion in products to the US annually. This move follows recent 50% tariffs imposed on India for purchasing Russian oil, as bilateral trade negotiations continue.